<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132964">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107378</url>
  </required_header>
  <id_info>
    <org_study_id>SOV03</org_study_id>
    <nct_id>NCT02107378</nct_id>
  </id_info>
  <brief_title>Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma</brief_title>
  <official_title>A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care
      chemotherapy may result in prolongation of Overall Survival (OS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival (all cause mortality)</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per modified RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>0, 8, 16, ,24, 32, 40, 48, 56, 64, 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological Progression Free Interval</measure>
    <time_frame>0, 8, 16, 24, 32, 40, 48, 56, 64, 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of Life via Functional Assessment of Cancer Therapy-Ovarian</measure>
    <time_frame>0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epithelial Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>DCVAC/OvCa in parallel with chemo (SoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with DCVAC/OvCa and Standard of Care (SoC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (Chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa</intervention_name>
    <description>DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin</description>
    <arm_group_label>DCVAC/OvCa in parallel with chemo (SoC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (Paclitaxel or topotecan or doxorubicin)</intervention_name>
    <description>Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy</description>
    <arm_group_label>Standard of Care (Chemotherapy)</arm_group_label>
    <other_name>Paclitaxel</other_name>
    <other_name>topotecan</other_name>
    <other_name>doxorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18 years or older

          -  Histologically confirmed International Federation of Gynecology and Obstetrics (FIGO)
             Stage III epithelial ovarian, primary peritoneal, or fallopian tube carcinoma
             (serous, endometrioid or mucinous), who have undergone initial surgery or interval
             debulking surgery but have not reached complete remission of more than 6 months after
             first line platinum based chemotherapy, for one of the following reasons

          -  Patients are platinum-refractory (no response)

          -  Complete remission was not reached (partial responders)

          -  Relapse within ≤6 months of remission (Platinum-resistant)

          -  Platinum-based chemotherapy failure should have been confirmed by computerized
             tomography (CT)/magnetic resonance imaging (MRI) scan (Platinum-resistant) or by
             finding described as 'did not reach complete clinical remission' (Platinum-refractory
             or Platinum-partial response) Patients must have at least one measureable target
             lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
             criteria

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0−2

        Exclusion Criteria:

          -  FIGO I,II,IV epithelial ovarian cancer

          -  FIGO III clear cells epithelial ovarian cancer

          -  Non-epithelial ovarian cancer

          -  Borderline tumors (tumors of low malignant potential)

          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example
             chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy,
             vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first
             line Platinum-based chemotherapy (with or without bevacizumab)

          -  Previous radiotherapy to the abdomen and pelvis

          -  Malignancy other than epithelial ovarian cancer, except those that have been in
             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the
             cervix or non-melanoma skin carcinomas

          -  Clinically significant cardiovascular disease

          -  Active autoimmune disease requiring treatment

          -  History of severe forms of primary immune deficiencies

          -  Systemic immunosuppressive therapy for any reason
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Kapsa</last_name>
    <phone>(+420) 2241 74448)</phone>
    <email>kapsa@sotio.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice</city>
        <zip>45-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Serous</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Platinum resistant (pt)</keyword>
  <keyword>Ovarian Cancer (OvCa)</keyword>
  <keyword>Biological</keyword>
  <keyword>Vaccine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
